The algorithms for treating psoriatic arthritis (PsA) are unique among rheumatic diseases because most PsA patients receive prior treatment by dermatologists for psoriasis, with many of the same therapies that are frequently used for PsA. Therefore, biological and targeted synthetic DMARDs are more frequently used as early-line therapies after the diagnosis of PsA. Understanding the use of non-TNF inhibitors, namely, IL-12/23 inhibitors, IL-17 inhibitors, PDE-4 inhibitors, JAK inhibitors, and co-stimulatory modulators, is crucial for pharmaceutical companies to properly manage their brands in the PsA market. Analysis of claims data and electronic health records provides an objective lens to see how physicians prescribe therapies and what the clinical profiles of treated patients are.

QuestionsUESTIONS AnsweredNSWERED

· What is the patient share in PsA for IL-17 inhibitors and other key segments?

· What are the demographic characteristics and clinical profiles of PsA patients on Otezla and Xeljanz?

· What are the key risk factors, comorbidities, and co-prescribed/additional therapies by patient segment for PsA?

· How do patient cohorts for PsA compare in care utilization and outcomes (physician visits and other healthcare encounters)?

· What are the reimbursed and out-of-pocket costs?

· What insurance type do PsA patients have?

Table of contents

  • Psoriatic Arthritis - Current Treatment - Detailed, Expanded Analysis: Patient Profiler (US)
    • Patient Profiler - Psoriatic Arthritis PPT [July 2018]
    • Please Note:

Author(s): Hailing Yang, PhD

Hailing Yang, Ph.D., is an analyst on the Immune and Inflammatory research team at Decision Resources Group, focusing primarily on psoriasis and psoriatic arthritis. In this role, he conducts primary research via interviews/surveys with medical experts and write market analysis deliverables designed for key decision-makers within the biopharmaceutical industry.

Prior to joining DRG, Dr. Yang worked at Selecta Biosciences and Bioss USA Antibodies as a consultant. He studied brain cancer and received a Ph.D. from Tufts University, where he held an executive role for Tufts New England Case Competition. Dr. Yang earned a B.S. from Wuhan University in China.


Related Reports

Psoriatic Arthritis - Landscape & Forecast - Disease Landscape & Forecast

A series of launches are expected to continue to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market in the next ten years and...

View Details

Psoriatic Arthritis | Disease Landscape and Forecast | G7 | 2020

A series of launches are expected to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market over the next 10 years and challenge the dominance of the TNF inhibitors; the...

View Details

Psoriatic Arthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US) Dashboard

Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (

View Details

Psoriatic Arthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US)

Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (

View Details